Who is sponsoring NCT04575636?

NCT04575636 is sponsored by Maastricht University Medical Center.

What drugs are being tested in NCT04575636?

Interventions in NCT04575636: Magnetic Resonance Lymphography.

What condition does NCT04575636 study?

NCT04575636 studies Lymphedema of Upper Limb.

Is NCT04575636 still recruiting?

NCT04575636 is currently completed. Last updated 23 October 2023.

Last reviewed 2023-10-23 · How we verify

NCT04575636

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MRL in the Upper Extremity

Completed NA Last updated 23 October 2023

What this trial tests

NA trial testing Magnetic Resonance Lymphography in Lymphedema of Upper Limb in 20 participants. Completed in 31 August 2023.

Timeline

10 September 2020

Primary endpoint
31 December 2022

31 August 2023

Quick facts

Lead sponsor	Maastricht University Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	20
Start date	10 September 2020
Primary completion	31 December 2022
Estimated completion	31 August 2023
Sites	1 location across Netherlands

Drugs / interventions tested

Magnetic Resonance Lymphography

Conditions studied

Lymphedema of Upper Limb — all drugs for Lymphedema of Upper Limb →

Sponsor

Maastricht University Medical Center

Who can join

Adults 18 to 99, any sex, with Lymphedema of Upper Limb. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Objective: The aim of this study is to examine the feasibility and applicability of the MRL protocol for the upper extremity in Maastricht University Medical Center, and to examine the differences of the lymphatic system between lymphedema patients and healthy volunteers. Study design: An explorative study of an MRL protocol for the upper extremity in Maastricht University Medical Center+. Study population: There are two study groups. The first group (n=10) consists of patients with secondary lymphedema in the upper extremity. The second group (n=10) consists of healthy volunteers. Intervention (if applicable): All participants will undergo an MRL examination with the same protocol, developed in a previous 'proof of principle' study, in the Maastricht University Medical Center+. After localizer scans, a T2-weighted sequence is used. Then a T1-weighted sequence will be made before the injection of contrast. After the injection of the contrast agent a T1-weighted sequences of the upper and lower arm are performed alternately. Main study parameters/endpoints: The primary outcome is to determine the feasibility and applicability of the MRL protocol by evaluating the images of the upper extremity in patients with secondary lymphedema and healthy subjects. The secondary outcome is to assess the value of MRL in staging lymphedema.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Lymphedema of Upper Limb

Currently open trials in the same condition.

NCT06264817 — Auto-Adjustable MOBIDERm Autofit Armsleeve in the Management of Upper Limb Lymphedema. · NA · recruiting
NCT06302361 — Lymphovenous Anastomosis for Breast Cancer Lymphedema · NA · active not recruiting
NCT06082349 — The N-LVA Study: RCT Comparing LVA vs. Sham Surgery in Cancer-related Lymphedema · NA · recruiting
NCT05441943 — Lymphaticovenous Anastomosis as Treatment for Lymphedema · NA · active not recruiting
NCT05142800 — Screening For BCRL In Targeted Therapy For Breast Cancer · active not recruiting

Other Maastricht University Medical Center trials

Trials by the same sponsor.

NCT04603261 — Time to Excretion of Contrast, a Maastricht Prospective Observational Study · withdrawn
NCT04598516 — Maastricht Investigation of Renal Function in Absence of- and Post- Contrast in Patients With eGFR LEss Than 30 · withdrawn
NCT04597892 — Efficacy of Point-Of-Care Creatinine Assays in Patients With eGFR <30 Receiving Intravascular Contrast · withdrawn
NCT07287358 — Optimal Cerebral Perfusion Pressure Guided Therapy: Assessment of Target Effectiveness - II · NA · not yet recruiting
NCT07501780 — Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04575636 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Maastricht University Medical Center
Last refreshed: 23 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04575636.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing